Numab Therapeutics
PrivateLast Round
Series C
Extension
Jan 9, 2025
Est. Valuation
$1.25B
Total Funding Raised
$187.6M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Numab Therapeutics is a biotechnology company that develops multispecific antibody-based immunotherapies for the treatment of chronic inflammation and cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Numab Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Numab Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Jan 9, 2025 | ||||
| M&A | Jul 11, 2024 | ||||
| Series C | May 20, 2021 | ||||
| Series B | Mar 9, 2020 |
Key People
Founding team and executive leadership
Numab Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion | Series C Extension |
| Octagon Capital Advisors | Series C Extension, Series C |
| Cormorant Asset Management | Series C, Series C Extension |
| Flerie Invest | Series C Extension, Series C |
| HBM Healthcare Investments | Series C Extension |
| Novo Holdings | Series C Extension, Series C |
| BVF Partners L.P. | Series C Extension, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Monthly visitors grew 121% MoM, reaching 4.1K.
- Sep 25, 2025
Achieved an unspecified milestone in collaboration with Boehringer Ingelheim.
Numab Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Numab Therapeutics's valuation, stock price, and market status.